HUTCHMED (NASDAQ:HCM) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a report published on Friday.

HUTCHMED Trading Down 7.1 %

Shares of HCM stock opened at $14.99 on Friday. HUTCHMED has a 12-month low of $12.84 and a 12-month high of $21.92. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The company has a 50 day moving average of $14.69 and a 200-day moving average of $16.51.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HCM. Public Employees Retirement System of Ohio purchased a new position in HUTCHMED in the 3rd quarter valued at approximately $35,000. Barclays PLC grew its position in shares of HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares during the period. Summit Trail Advisors LLC increased its holdings in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after purchasing an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC bought a new position in shares of HUTCHMED in the fourth quarter worth $230,000. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.